LAVA Therapeutics NV (LVTX) Fundamental Analysis & Valuation

NASDAQ:LVTX • NL0015000AG6

Current stock price

1.74 USD
-0.07 (-3.87%)
Last:

This LVTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LVTX Profitability Analysis

1.1 Basic Checks

  • In the past year LVTX has reported negative net income.
  • In the past 5 years LVTX always reported negative net income.
  • In the past 5 years LVTX reported 4 times negative operating cash flow.
LVTX Yearly Net Income VS EBIT VS OCF VS FCFLVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • With a Return On Assets value of -69.12%, LVTX is not doing good in the industry: 61.68% of the companies in the same industry are doing better.
  • LVTX has a worse Return On Equity (-190.76%) than 68.22% of its industry peers.
Industry RankSector Rank
ROA -69.12%
ROE -190.76%
ROIC N/A
ROA(3y)-31.44%
ROA(5y)-40.51%
ROE(3y)-69.63%
ROE(5y)-90.26%
ROIC(3y)N/A
ROIC(5y)N/A
LVTX Yearly ROA, ROE, ROICLVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • LVTX's Gross Margin of 100.00% is amongst the best of the industry. LVTX outperforms 99.07% of its industry peers.
  • LVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LVTX Yearly Profit, Operating, Gross MarginsLVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LVTX Health Analysis

2.1 Basic Checks

  • LVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LVTX remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for LVTX has been increased compared to 5 years ago.
  • The debt/assets ratio for LVTX is higher compared to a year ago.
LVTX Yearly Shares OutstandingLVTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
LVTX Yearly Total Debt VS Total AssetsLVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • LVTX has an Altman-Z score of -4.42. This is a bad value and indicates that LVTX is not financially healthy and even has some risk of bankruptcy.
  • LVTX has a Altman-Z score of -4.42. This is in the lower half of the industry: LVTX underperforms 60.56% of its industry peers.
  • There is no outstanding debt for LVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.42
ROIC/WACCN/A
WACC7.09%
LVTX Yearly LT Debt VS Equity VS FCFLVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 6.73 indicates that LVTX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.73, LVTX is doing good in the industry, outperforming 68.41% of the companies in the same industry.
  • A Quick Ratio of 6.73 indicates that LVTX has no problem at all paying its short term obligations.
  • LVTX's Quick ratio of 6.73 is fine compared to the rest of the industry. LVTX outperforms 68.60% of its industry peers.
Industry RankSector Rank
Current Ratio 6.73
Quick Ratio 6.73
LVTX Yearly Current Assets VS Current LiabilitesLVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LVTX Growth Analysis

3.1 Past

  • LVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.50%, which is quite good.
  • The Revenue has grown by 77.01% in the past year. This is a very strong growth!
  • The Revenue has been growing by 33.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
Revenue 1Y (TTM)77.01%
Revenue growth 3Y33.82%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LVTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.53% on average per year.
  • Based on estimates for the next years, LVTX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y7.87%
EPS Next 2Y20.48%
EPS Next 3Y16.82%
EPS Next 5Y11.53%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LVTX Yearly Revenue VS EstimatesLVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 5M 10M 15M
LVTX Yearly EPS VS EstimatesLVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. LVTX Valuation Analysis

4.1 Price/Earnings Ratio

  • LVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LVTX Price Earnings VS Forward Price EarningsLVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LVTX Per share dataLVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • LVTX's earnings are expected to grow with 16.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.48%
EPS Next 3Y16.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LVTX Dividend Analysis

5.1 Amount

  • LVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LVTX Fundamentals: All Metrics, Ratios and Statistics

LAVA Therapeutics NV

NASDAQ:LVTX (11/20/2025, 8:00:00 PM)

1.74

-0.07 (-3.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-26
Inst Owners27.59%
Inst Owner Change-100%
Ins Owners0.73%
Ins Owner Change-69.19%
Market Cap45.78M
Revenue(TTM)11.98M
Net Income(TTM)-49.19M
Analysts45.71
Price Target1.4 (-19.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)60.08%
Min EPS beat(2)53.47%
Max EPS beat(2)66.68%
EPS beat(4)3
Avg EPS beat(4)24.77%
Min EPS beat(4)-36.66%
Max EPS beat(4)66.68%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)10
Avg EPS beat(12)26.68%
EPS beat(16)14
Avg EPS beat(16)24.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.82
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.46
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.12%
ROE -190.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-31.44%
ROA(5y)-40.51%
ROE(3y)-69.63%
ROE(5y)-90.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.73
Quick Ratio 6.73
Altman-Z -4.42
F-ScoreN/A
WACC7.09%
ROIC/WACCN/A
Cap/Depr(3y)66.67%
Cap/Depr(5y)88.88%
Cap/Sales(3y)4.68%
Cap/Sales(5y)8.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.3%
EPS Next Y7.87%
EPS Next 2Y20.48%
EPS Next 3Y16.82%
EPS Next 5Y11.53%
Revenue 1Y (TTM)77.01%
Revenue growth 3Y33.82%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-82.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.48%
OCF growth 3YN/A
OCF growth 5YN/A

LAVA Therapeutics NV / LVTX Fundamental Analysis FAQ

What is the fundamental rating for LVTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LVTX.


Can you provide the valuation status for LAVA Therapeutics NV?

ChartMill assigns a valuation rating of 0 / 10 to LAVA Therapeutics NV (LVTX). This can be considered as Overvalued.


How profitable is LAVA Therapeutics NV (LVTX) stock?

LAVA Therapeutics NV (LVTX) has a profitability rating of 1 / 10.